Drug Profile
Exisulind - OSI Pharmaceuticals
Alternative Names: Aptosyn; FGN 1™; Prevatac™; Sulindac sulfoneLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class Antineoplastics; Small molecules; Sulfones
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cyclic GMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Familial adenomatous polyposis; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer